Literature DB >> 16971437

Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Lakshmanan Govindasamy1, Eric Padron, Robert McKenna, Nicholas Muzyczka, Nikola Kaludov, John A Chiorini, Mavis Agbandje-McKenna.   

Abstract

The adeno-associated viruses (AAVs) can package and deliver foreign DNA into cells for corrective gene delivery applications. The AAV serotypes have distinct cell binding, transduction, and antigenic characteristics that have been shown to be dictated by the capsid viral protein (VP) sequence. To understand the contribution of capsid structure to these properties, we have determined the crystal structure of AAV serotype 4 (AAV4), one of the most diverse serotypes with respect to capsid protein sequence and antigenic reactivity. Structural comparison of AAV4 to AAV2 shows conservation of the core beta strands (betaB to betaI) and helical (alphaA) secondary structure elements, which also exist in all other known parvovirus structures. However, surface loop variations (I to IX), some containing compensating structural insertions and deletions in adjacent regions, result in local topological differences on the capsid surface. These include AAV4 having a deeper twofold depression, wider and rounder protrusions surrounding the threefold axes, and a different topology at the top of the fivefold channel from that of AAV2. Also, the previously observed "valleys" between the threefold protrusions, containing AAV2's heparin binding residues, are narrower in AAV4. The observed differences in loop topologies at subunit interfaces are consistent with the inability of AAV2 and AAV4 VPs to combine for mosaic capsid formation in efforts to engineer novel tropisms. Significantly, all of the surface loop variations are associated with amino acids reported to affect receptor recognition, transduction, and anticapsid antibody reactivity for AAV2. This observation suggests that these capsid regions may also play similar roles in the other AAV serotypes.

Entities:  

Mesh:

Year:  2006        PMID: 16971437      PMCID: PMC1642620          DOI: 10.1128/JVI.01536-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.

Authors:  H Chao; Y Liu; J Rabinowitz; C Li; R J Samulski; C E Walsh
Journal:  Mol Ther       Date:  2000-12       Impact factor: 11.454

2.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

4.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

Authors:  J G Flannery; S Zolotukhin; M I Vaquero; M M LaVail; N Muzyczka; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Canine parvovirus capsid structure, analyzed at 2.9 A resolution.

Authors:  Q Xie; M S Chapman
Journal:  J Mol Biol       Date:  1996-12-06       Impact factor: 5.469

6.  Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry.

Authors:  Glen A Farr; Li-guo Zhang; Peter Tattersall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-11       Impact factor: 11.205

7.  Generation and characterization of chimeric recombinant AAV vectors.

Authors:  Bernd Hauck; Ling Chen; Weidong Xiao
Journal:  Mol Ther       Date:  2003-03       Impact factor: 11.454

8.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  The structure of human parvovirus B19.

Authors:  Bärbel Kaufmann; Alan A Simpson; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

10.  Functional implications of the structure of the murine parvovirus, minute virus of mice.

Authors:  M Agbandje-McKenna; A L Llamas-Saiz; F Wang; P Tattersall; M G Rossmann
Journal:  Structure       Date:  1998-11-15       Impact factor: 5.006

View more
  100 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

2.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

3.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

4.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

Review 5.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

6.  Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Authors:  Sanford L Boye; Antonette Bennett; Miranda L Scalabrino; K Tyler McCullough; Kim Van Vliet; Shreyasi Choudhury; Qing Ruan; James Peterson; Mavis Agbandje-McKenna; Shannon E Boye
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 7.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

8.  Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.

Authors:  Dawn E Bowles; Scott W J McPhee; Chengwen Li; Steven J Gray; Jade J Samulski; Angelique S Camp; Juan Li; Bing Wang; Paul E Monahan; Joseph E Rabinowitz; Joshua C Grieger; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Xiao Xiao; R Jude Samulski
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

9.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1.

Authors:  Edward B Miller; Brittney Gurda-Whitaker; Lakshmanan Govindasamy; Robert McKenna; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

10.  A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

Authors:  Lin Yang; Jiangang Jiang; Lauren M Drouin; Mavis Agbandje-McKenna; Chunlian Chen; Chunping Qiao; Dongqiuye Pu; Xiaoyun Hu; Da-Zhi Wang; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.